Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2422-2430

  Liang, Song ^a   Guo, Renhua ^a   Zhang, Zhihong ^a   Liu, Dongxiao ^b   Xu, Hao ^a   Xu, Zekuan ^a   Wang, Xuerong ^a   Yang, Li ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Akt; Eukaryotic translation initiation factor 4E; Gastric cancer; Perifosine

Indexed keywords

INITIATION FACTOR 4E; PERIFOSINE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; EIF4E ONCOGENE; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; DOWN-REGULATION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84876277464     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2397     Document Type: Article

References (25)

1. Avdulov S, Li S, Michalek V, et al: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5: 553-563, 2004. (Pubitemid 38748917)
2. Chen CN, Hsieh FJ, Cheng YM, Lee PH and Chang KJ: Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 86: 22-27, 2004.
3. De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004. (Pubitemid 38638830)
4. Dong K, Wang R, Wang X, et al: Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 113: 443-456, 2009.
5. Choi CH, Lee JS, Kim SR, et al: Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol 137: 463-469, 2011.
6. Herbert TP, Fahraeus R, Prescott A, Lane DP and Proud CG: Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 10: 793-796, 2000. (Pubitemid 30466944)
7. Ge Y, Cheng R, Zhou Y, et al: Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E. Mol Cell Biochem 368: 17-25, 2012.
8. Zhou FF, Yan M, Guo GF, et al: Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol 28: 1302-1307, 2011.
9. Gills JJ and Dennis PA: Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11: 102-110, 2009.
10. Elrod HA, Lin YD, Yue P, et al: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 6: 2029-2038, 2007. (Pubitemid 47052493)
11. Papa V, Tazzari PL, Chiarini F, et al: Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22: 147-160, 2008.
12. Tazzari PL, Tabellini G, Ricci F, et al: Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 68: 9394-9403, 2008.
13. Leighl NB, Dent S, Clemons M, et al: A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 108: 87-92, 2008. (Pubitemid 351623244)
14. Ghobrial IM, Roccaro A, Hong F, et al: Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 16: 1033-1041, 2010.
15. Cho DC, Hutson TE, Samlowski W, et al: Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 118: 6055-6062, 2012.
16. Ma Z, Zhu L, Luo X, Zhai S, Li P and Wang X: Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells. Cancer Biol Ther 13: 1009-1017, 2012.
17. Wang S, Rosenwald IB, Hutzler MJ, et al: Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 155: 247-255, 1999. (Pubitemid 29318722)
18. Muta D, Makino K, Nakamura H, Yano S, Kudo M and Kuratsu J: Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neurooncol 101: 33-39, 2011.
19. Soni A, Akcakanat A, Singh G, et al: eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7: 1782-1788, 2008.
20. Fan SQ, Ramalingam SS, Kauh J, Xu ZH, Khuri FR and Sun SY: Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 8: 1463-1469, 2009.
21. Wheater MJ, Johnson PW and Blaydes JP: The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther 10: 728-735, 2010.
22. Fischer PM: Cap in hand: targeting eIF4E. Cell Cycle 8: 2535-2541, 2009.
23. Jia Y, Polunovsky V, Bitterman PB and Wagner CR: Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. Med Res Rev 32: 786-814, 2012.
24. Hideshima T, Catley L, Yasui H, et al: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062, 2006. (Pubitemid 43726814)
25. Yoshizawa A, Fukuoka J, Shimizu S, et al: Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16: 240-248, 2010.